Finally, we assessed whether combinatorial pharmacological targeting of multiple LSD1‐CoREST complex members has a synergistic effect on treatment response by combining histone deacetylase (HDAC) and LSD1 inhibitors, as this has been shown for other cancers (Kalin et al, 2018; Anastas et al, 2019). This evidence concerns the gene HDAC9 and cancer.